CStone Pharmaceuticals (2616) investor relations material

Executive summary

• 2025 marked a pivotal year with significant R&D progress, especially for Pipeline 2.0 assets, and expanded global commercialization efforts.

• Revenue declined 33.8% year-over-year to RMB269.6 million, mainly due to price adjustments, one-off channel compensation for NRDL negotiation, and lower license fee income after significant one-time payments in 2024.

• Loss for the year widened to RMB437.0 million, driven by lower gross profit and higher R&D expenses; adjusted net loss was RMB266.1 million, excluding one-time NRDL impacts and share-based payments.

• Cash and cash equivalents plus time deposits stood at RMB918.7 million at year-end, up 37% from the prior year.

• Major pipeline progress included CS2009 advancing to Phase II, global regulatory approvals for sugemalimab, and expanded partnerships for commercialization.

Financial highlights

• FY2025 revenue was RMB269.6 million, down 33.8% year-over-year, with pharmaceutical sales at RMB78.3 million, license fee income at RMB167.7 million, and royalty income at RMB23.6 million.

• Cost of revenue was RMB218.3 million (up 30.7% YoY), mainly due to inventory write-downs and early billing for pralsetinib supply.

• R&D expenses rose 140% YoY to RMB299.5 million, reflecting commitment to innovation.

• Administrative expenses were RMB89.0 million (up 14.4% YoY); selling and marketing expenses were RMB83.3 million (down 37.7% YoY).

• No dividend declared for the year.

Outlook and guidance

• Multiple Phase III registrational trials for CS2009 and CS5001 are planned to initiate by end of 2026.

• Anticipates revenue ramp-up in 2026 and beyond as pralsetinib benefits from NRDL inclusion.

• Continued expansion of global commercial partnerships and launches for CEJEMLY® and other assets.

• First-in-human trials for new ADC assets (CS5007, CS5006, CS5008) anticipated in 2026.

• Focus on accelerating clinical development of CS2009 and CS5001, advancing early-stage ADC candidates, and strengthening proprietary platforms.